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Peroxisome proliferators-activated receptors (PPARs) that are members of the nuclear receptor superfamily have three diﬀerent
isoforms: PPARα,P P A R δ,a n dP P A R γ. PPARs are ligand-activated transcription factors, and they are implicated in tumor
progression, diﬀerentiation, and apoptosis. Activation of PPAR isoforms lead to both anticarcinogenesis and anti-inﬂammatory
eﬀect.IthassofaridentiﬁedmanyPPARligandsincludingchemicalcompositionandnaturaloccurring.PPARligandsarereported
to activate PPAR signaling and exert cancer prevention and treatment in vitro and/or in vivo studies. Although the eﬀects depend
on the isoforms and the types of ligands, biological modulatory activities of PPARs in carcinogenesis and disease progression are
attracted for control or combat cancer development. This short review summarizes currently available data on the role of PPAR
ligands in carcinogenesis.
Copyright © 2008 Yumiko Yasui et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Peroxisome proliferators-activated receptors (PPARs) are
member of the nuclear hormone receptor superfamily that
were initially characterized as molecules that mediated the
proliferation of peroxisomes in rodent liver parenchymal
cells in response to the hypolipidemic drug cloﬁbrate [1].
Subsequently, PPARs have been shown to regulate the
expression of genes involved in a variety of biological
processes, including lipid metabolism and insulin sensitivity
[2, 3]. Three isotypes of PPAR exist; PPARα,P P A B β/δ or
simply δ,a n dP P A R γ which are known and they are encoded
by three separate genes and display distinctly diﬀerent tissue
distributions and functions. PPARα regulates numerous
aspects of fatty acid catabolism, where as PPARγ controls
adipocyte diﬀerentiation, systemic glucose levels, and lipid
homeostasis [4, 5]. PPARδ is involved in development,
embryo implantation, myelination of the corpus callosum,
lipid metabolism, and epidermal cell proliferation [6]. The
PPARs are ligand-dependent transcription factors that regu-
late target genes expression by binding to characteristic DNA
sequencestermedperoxisomeproliferatorsresponseelement
(PPREs) located in the 5 -ﬂanking region of target genes
[7, 8]. Each receptor binds to its PPRE as a heterodimer with
the receptor for 9-cis retinoic acid, the retinoid X receptor
(RXR) (Figure 1). Upon binding a ligand, the conformation
of a PPAR is altered and stabilized such that a binding cleft
is created, and recruitment of transcriptional coactivators
occurs. The result is an increase in gene transcription,
therefore PPARs are able to regulate such divers eﬀects as cell
proliferation, diﬀerentiation, or apoptosis.
2. PPARα LIGANDS AND CARCINOGENESIS
PPARα is the ﬁrst member of this nuclear receptor subclass
to be cloned [9]. PPARα is expressed preferentially in the
liver [10] and tissues with high fatty acid catabolism, such
as the kidney, heart, skeletal muscle, and brown fat [11–
13]. The PPARα isotype is the cellular target for leukotriene
B 4( L T B 4 )ﬁ b r a t e ss u c ha sb e z a ﬁ b r a t ea n df e n o ﬁ b r a t e ,
which are hypolipidemic drugs widely used for reducing
triglyceride levels, a risk of cardiovascular diseases. Several
studies have established a link between PPARα activation
andepidermaldiﬀerentiation.Fibratesinducediﬀerentiation
and inhibit proliferation in normal and hyperproliferating
mouse epidermis and regulate apoptosis, but are inactive
in PPARα-deﬁcient mice [14, 15]. Farnesol also stimulates
PPARα-dependentdiﬀerentiationinepidermalkeratinocytes
[16]. Topical PPARα ligands have weak preventive eﬀects
on tumor promotion in mouse skin, despite upregulation
of PPARα in untreated tumors compared with normal
epidermis [17]. These observations suggest that the use of2 PPAR Research
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Figure 1: PPAR activation pathway and its target genes.
PPARα activators may have chemopreventive properties in
skin carcinogenesis. PPARα expression is also upregulated in
human prostate adenocarcinomas [18]. In addition, PPARα
ligands suppress the growth of several cancer lines, including
colon [19], endometrial [20], and breast [21]i nv i v oo r
in vitro. PPARα ligands are able to suppress the metastatic
potential of melanoma cells in vivo and in vitro [22, 23].
More recently, a PPARα ligand WY14643 suppresses both
endothelial cell proliferation and tumorigenesis in a PPARα-
dependent manner [24]. These data suggest that certain
PPARα ligands may act as antitumor agents, although
the exact mechanisms remain unclear. PPARα activation
has been associated with both anti and proinﬂammatory
actions in rodents. PPARα ligands reduce expression of
inﬂammatorymarkers[25].Incontrast,theexpressionofthe
inﬂammatory mediator cyclooxygenase (COX)-2 in human
breastandcoloncancercellsisupregulatedbyPPARαligands
[26].TheincreasedCOX-2expressionisknowntolinktothe
risk of epithelial malignancies [27]. These ﬁndings indicate
that PPARα ligands may be interesting candidates for the
chemoprevention of several types of cancers, but we should
consider negative face of inﬂuence of PPARα ligands on
cancer development.
3. PPARδ LIGANDS AND CARCINOGENESIS
A number of reports have described a variety of biological
functions of the PPARα and γ isotypes. These two isotypes
also have clinical signiﬁcance in the treatment of dyslipi-
deamia and type II diabetes mellitus [28]. In contrast, less
is known about the physiological role of the PPARδ isoform,
although there is some evidence supporting its involvement
in embryo implantation and development [6, 29], epidermal
maturation and wound healing [30], and regulation of fatty
acid metabolism [31]. Recently, the eﬀect of PPARδ function
on colon carcinogenesis has been reported. However, the
role of PPARδ in colon cancer is still unclear, as there are
data suggesting that it either inhibits or promotes colon
carcinogenesis. PPARδ expression is increased in colon
tumor cells with a mutant Apc (adenomatous polyposis coli)
allele (min) [32]. The number of polyps was the same
among the multiple intestinal neoplasia (Min) mice that
were Ppard−/−, Ppard+/−,o rPpard+/+. These ﬁndings suggest
that PPARδ is not essential for colon carcinogenesis, but
PPARδ may aﬀect size and/or growth of polyps [29]. The
moststrikingresultswereprovidedbyastudydemonstrating
that in PPARδ deﬁcient (Ppard−/−)m i c e ,b o t hMin mutants
and those with chemically induced cancers, colon polyp
formation was signiﬁcantly greater in those nullizygous for
PPARδ [33]. These results suggest that PPARδ attenuates
colon carcinogenesis. On the other hand, the following
observations strongly suggest that PPARδ enhances colon
cancer formation. PPARδ was elevated in colon cancer cells
and was repressed by APC gene via the β-catenin/Tcf-4
response elements in its promoter [32]. Genetic disruption
of PPARδ decreases the tumorigenicity of human colon
cancer cells [34]. Nitric oxide donating aspirin is reported to
suppress intestinal tumors in Min mice and downregulates
the expression of PPARδ and enhance apoptosis and perhaps
atypicalcelldeath[35].ThissuggeststhatPPARδ contributes
to intestinal carcinogenesis.
GW501516 was shown to be a PPARδ subtype-selective
ligand using combinatorial chemistry and structure-based
drug design [36]. There are some reports describing the
eﬀects of PPARδ ligand on colon carcinogenesis. Exposure
of APCmin/+ mice to the GW501516 resulted in activation
of PPARδ and signiﬁcant acceleration of intestinal adenoma
growth [37]. Furthermore, PPARδ activation by PPARδ
ligandpromotestumorgrowthbyinhibitingepithelialtumor
cell apoptosis through activation of a VEGF autocrine
signaling loop in APCmin/+ mice [38]. GW501516 stimulates
proliferation of human breast, prostate, and hepatocellular
carcinoma cells [39, 40]. In a mouse mammary tumori-
genesis model, GW501516 activates 3-phospholinositide-
dependentproteinkinase-1thatisoncogenicwhenexpressed
in mammary ductal cells, and leads to accelerated tumor
formation [41]. From these ﬁndings, PPARδ selective-ligand
tends to exert enhancing eﬀects on carcinogenesis, while its
antagonists are expected to prevention and/or treatment of
cancer.Yumiko Yasui et al. 3
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Figure 2: Synthetic and naturally occurring ligands for PPARγ.
4. PPARγ LIGANDS AND CARCINOGENESIS
PPARγ plays an important role in the regulation of prolif-
eration and diﬀerentiation of several cell types. PPARγ is
known to be expressed in various organs, including adipose
tissue [42], mammary glands [43], small intestine [44], lung
[45], colon [44], and stomach [46], and is also upregulated
in various types of cancer cells.
This receptor has the ability to bind a variety of small
lipophilic compounds derived from both metabolism and
nutrition. These ligands, in turn, direct cofactor recruitment
to PPARγ, regulating the transcription of genes in a variety
of complex metabolic pathways. Several speciﬁc ligands
(Figure 2) have been identiﬁed, such as the thiazolidine-
diones (including pioglitazone, rosiglitazone, and troglita-
zone), naturally occurring lipid, polyunsaturated fatty acids
(PUFA) (including arachidonic, oleic, and linoleic acid) and
the cyclopentenone prostaglandin (PG) 15-deoxy Delta12,14-
PGJ2, a metabolite of PGD2.P P A R γ ligands have been
reported to induce cell diﬀerentiation and apoptosis in sev-
eral types of cancer [47–51], suggesting potential application
as anticancer agents. Furthermore, some reports recently
suggested that PPARγ ligands can be used as chemopreven-
tive agents for colon, breast, and tongue carcinogenesis [52–
54].
The most widely used synthetic agents belong to the
thiazolidinedione class of antidiabetic drugs (also referred
to as glitazones). These include ciglitazone, troglitazone,
pioglitazone, rosiglitazone, and LY171.833. Pioglitazone,
rosiglitazone, and troglitazone have already been used clin-
ically to treat type 2 diabetes, making use of the ability of
synthetic PPARγ ligands to sensitize insulin and to lower
blood glucose concentration. Recent evidence indicates that
certain thiazolidinedione members, especially troglitazone
and ciglitazone, exhibit moderate anitproliferative activities
against epithelial-derived human cancer cell lines, including
those of prostate [55], breast [56], colon [57], thyroid [51],
lung [58], and pituitary carcinoma [50]. PPARγ is known to
be expressedin a variety ofcancer,andthe treatmentofthese
cancer cells with PPARγ ligands often induces cell diﬀeren-
tiation and apoptosis [47–51], and exerts antiproliferative
eﬀects on human colon cancer [59], breast cancer [47],
pituitary adenomas [50], gastric cancer [60], and bladder
cancer [61]. Furthermore, postulated mechanisms by which
PPARγ ligands exert their eﬀects include modulation of the
oncogenic Wnt pathway, inhibition of nuclear factor kappaB
(NF-κB), and modulation of cell cycle pro and antiapoptotic
proteins (Figure 3). Wnt signaling is a complex pathway in
which β-catenin binds to transcription factors in the nucleus
and plays a role as a central mediator in regulating cell pro-
liferation and diﬀerentiation [62]. PPARγ activation causes
ad e c r e a s ei nβ-catenin expression in adipocytes in vitro
and in normal intestinal mucosa in mice [63]. In the cul-
tured human monocytes, PPARγ inhibits NF-κBa c t i v a t i o n4 PPAR Research
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Figure 3: Molecular mechanisms for anticarcinogenic and/or chemopreventive eﬀects of PPARγ ligands.
thus inﬂuencing the transcription of both survival- and
apoptosis-related genes [64]. PPARγ activation also induces
the activation of the proapoptotic caspase-3 protein in
humanlivercancercelllinesandareductioninantiapoptotic
Bcl-2 and Bcl-XL protein level in human colon and gastric
cancer cell lines, respectively [65–67]. Furthermore, colon
cancer development is related to hyperlipidemia [68], with
clear links to high level of serum triglycerides (TGs) [69]. A
PPARγ ligand, pioglitazone, suppresses both hyperlipidemia
and intestinal polyp formation in the APC-deﬁcient mice in
conjunctionwithelevationoflipoproteinlipase(LPL),which
catalyzes TG hydrolysis [70].
We previously investigated the modifying eﬀects of
PPARγ or α ligands (troglitazone, pioglitazone, or bezaﬁ-
brate) on early phase of colon carcinogenesis with or
without colitis in male F344 rats [19, 71]. The role of
PPARγ in AOM-induced colon tumorigenesis was directly
demonstrated by the study showing that the incidence of
colonic tumors increased in the hemizygous knockout of
PPARγ thatreceivedAOM[72].Althoughthiazolidinediones
inhibit AOM-induced colon carcinogenesis in the wild type
mice, the observation using APC-deﬁcient mouse models
showed conﬂicting results regarding the eﬀects of PPARγ
ligand treatment [73–76] .T h i sm a yb ec a u s e db yu s eo f
diﬀerent PPARγ agonists (troglitazone versus pioglitazone),
and diﬀerent doses (100–2000ppm in diet) examined.
Colonic inﬂammation is associated with a high risk of
colorectal cancer (CRC) [77]. CRC is thus one of the
most serious complications of inﬂammatory bowel disease,
such as ulcerative colitis and Crohn’s disease [77]. In the
experiments, dietary administration of PPARα or γ lig-
ands eﬀectively suppressed azoxymethane (AOM)-induced
or dextran sodium sulfate (DSS)/AOM-induced aberrant
crypt foci, which are precursor lesions for colon carcinoma
(Table 1). Our ﬁndings suggested that synthetic PPARγ and
PPARα ligands are able to inhibit the early stages of colon
tumorigenesis with or without colitis, and the ﬁndings
were conﬁrmed by the study conducted by Osawa et al.
[78]. Furthermore, we demonstrated ligands for PPARγ and
PPARα inhibit colitis-related colon carcinogenesis [79] using
ourAOM/DSSmousemodel[80].Intheexperiment,dietary
administration(0.05%indietfor14weeks)withtroglitazone
and bezaﬁbrate signiﬁcantly inhibited both the incidence
and multiplicity of colonic adenocarcinoma induced by the
treatment with AOM/DSS, although bezaﬁbrate feeding did
not signiﬁcantly lower the multiplicity (Table 2). Dietary
exposure of troglitazone and bezaﬁbrate suppressed cell
proliferation and induced apoptosis and lowered immnore-
activity of COX-2, inducible nitric oxide, and nitrotyrosine
in the colonic malignancies.
PPARγ receptors are activated by certain lipophilic
ligands, such as PUFAs and eicosanoid derivatives. They
bind to the PPARγ receptor at micromolar concentrations.
The essential fatty acids (arachidonic acid, docosahexanoic
acid, and eicosapentaenoic acid) as well as modiﬁed oxi-
dized lipids (9-hydroxyoctadecanoic acid and 13-hydroxy-
octadecanoic acid) bind to and activate PPARγ [5]. Recently,
conjugated linoleic acid (CLA) was shown to act as a high
aﬃnity ligand and an activator of PPARγ [81]. Anticarcino-
genic activity of CLA is mediated by PPARγ activation in
susceptible tumors [81]. When treated with CLA, PPARγ
expression is increased, and APC and c-myc proteins are
downregulated in the human colon cancer cells, and ﬁnally
proliferation of cancer cells is inhibited by CLA [82–85]. In
fact, feeding with seed oils containing 9c,1 1 t,1 3 t-, 9c,1 1 t,
13c-, and 9t,1 1 t,1 3 c-conjugated linolenic acid, which are
converted to 9c,1 1 t-a n d9 t,1 1 t-CLA within colonic and
liver cells, suppresses AOM-induced colon carcinogenesis by
increased expression of PPARγ protein in the colon mucosa
[86–89].Yumiko Yasui et al. 5
Table 1: Eﬀects of PPAR ligands on ACF formation in rats.
Treatment (No. of mice) ACF/colon (% inhibition) ACs/colon (% inhibition)
AOM alone (12) 83 ± 6(a) 2.0 ±0.24
A O M+0 . 0 1 %t r o g l i t a z o n e ( 8 ) 6 8± 16 (18%) 1.7 ±0.21 (15%)
A O M+0 . 0 5 %t r o g l i t a z o n e ( 8 ) 5 5± 13(b) (34%) 1.5 ±0.13(c) (25%)
A O M+0 . 0 1 %b e z a ﬁ b r a t e( 8 ) 7 5 ±8 (10%) 2.0 ±0.20 (0%)
A O M+0 . 0 5 %b e z a ﬁ b r a t e( 8 ) 5 3 ± 9(d) (36%) 1.9 ±0.10 (5%)
None 0 0
1% DSS + AOM (10) 115 ± 22 2.4 ±0.29
1% DSS + AOM + 0.01% pioglitazone (7) 71 ± 24(e) (38%) 1.8 ±0.17(f) (25%)
1% DSS + AOM + 0.01% troglitazone(7) 57 ± 14(g) (50%) 1.6 ± 0.14(g) (33%)
1% DSS + AOM + 0.01% bezaﬁbrate (7) 59 ± 18(h) (49%) 1.7 ±0.16(i) (29%)
None 0 0
(a)Mean ±SD.
(b–d)Signiﬁcantly diﬀerent from the AOM alone group: (b) P < .01; (c) P < .005; and (d) P < .001.
(e–i)Signiﬁcantly diﬀerent from the DSS/AOM group: (e) P < .05; (f) P < .01; (g) P < .001; (h) P < .005; and (i) P < .002.
Table 2: Eﬀects of PPAR ligands on colon carcinogenesis in mice.
Treatment (no. of mice) Incidence/Multiplicity (% inhibition)
Total Adenoma Adenocarcinoma
AOM/DSS 100%/5.2 ± 3.0(a) 100%/2.1 ±1.8 100%/3.0 ±1.8
AOM/DSS/0.05% Troglitazone 90%/2.5 ±1.8(b)(52%,) 90%/1.6 ± 1.1 (24%) 40%(c)/1.2 ±2.5(b) (60%)
AOM/DSS/0.05% Bezaﬁbrate 80%/2.6 ±2.5(b)(50%) 70%/1.1 ±1.0(b) (48%) 60%(b)/1.8 ±2.6 (40%)
None 0%/0 0%/0 0%/0
(a)Mean ±SD.
(b,c)Signiﬁcantly diﬀerent from the AOM/DSS group: (b) P < .05; and (c) P < .01.
5. CLINICAL TRIAL FOR PPARγ LIGANDS
AGAINST TUMORS
There are several clinical studies on the eﬀects of PPARγ
ligands on malignancies (Table 3). The beneﬁcial eﬀects
of glitazones on liposarcomas have been demonstrated in
a small clinical trial [90]. Three patients with interme-
diate to high-grade liposarcomas were given troglitazone
(800mg/day orally). In the patients, diﬀerentiation of the
neoplasms occurred as revealed by histological and bio-
chemical analysis. The clinical outcome of these patients
was not reported, but the therapy was well tolarated [90].
However, a phase II study on 12 patients with liposar-
coma showed that the PPARγ ligand rosiglitazone did not
signiﬁcantly improve clinical outcome [94]. In prostate,
PPARγ immunoreactivitywassigniﬁcantlyhigherinprostate
cancer and prostatic intraepithelial neoplasia than in those
with benign prostate hyperplasia and with healthy prostate
[98]. A high incidence of prolonged stabilization of serum
prostate-speciﬁc antigen (PSA) was observed in a phase
II clinical study, where patients with advances prostate
cancer who had no symptoms of metastasis were treated
with troglitazone (800mg/day orally). Moreover, one patient
had a striking decrease in PSA concentration to almost
undetectableamounts[91].Ina75-year-oldmanwithoccult
recurrent prostate cancer showed a decrease in PSA after
oral treatment with toroglitazone (600–800mg/day for 1.5
years) [92]. Thus, PPARγ is expressed in prostate cancer and
activation of PPARγ might oﬀer an additional therapeutic
option for treatment of prostate cancer in the near future.
At present, most of the available data suggest that PPARγ
has antineoplastic eﬀect on malignant neoplasms [99],
including colonic malignancies. However, in a clinical phase
II study on CRC, orally administrated troglitazone did not
lengthen median progression-free survival or median sur-
vival in 25 patients with chemotherapy-resistant metastatic
colon carcinoma [93]. In phase II study [95] for the use
of troglitazone to treat patients with advanced refractory
breast cancer, no objective tumor response was observed.
However, the study was incomplete because troglitazone was
withdrawn from commercial availability after a warning by
the US Food and Drug Administration about hepatic toxic
eﬀects. On the other hand, it is important to note that
neither hormone status of the tumors nor the amount of
PPARγ protein is assessed before patients were included
in the study. In an open labeled phase II study where
ten patients with thyroglobulin-positive and radioiodine-
negative diﬀerentiated thyroid cancer were enrolled and they
weregivenoralrosiglitazone treatment(4mg/dayfor1week,
then 8mg per day for 7 weeks), rosiglitazone treatment
resulted in a 40% partial response rate, but no complete
responses, and the expression level of PPARγ mRNA and
protein in the neoplasm appeared unrelated to rosiglitazone
treatment response [96]. The ﬁndings also suggest that6 PPAR Research
Table 3: Clinical trials on the anticancer eﬀects of PPARγ ligands.
Clinical trials Drug Results Reference no.
Patients with intermediate to
high-grade liposarcomas (case
reports)
Troglitazone Histlogical and biochemical diﬀerentiation [90]
Phase II study on patients with
histologically-conﬁrmed prostate
cancer and no symptomatic
metastatic disease
Troglitazone Lengthened stabilization of prostate-speciﬁc antigen [91]
75-year-old patient with an
occult recurrent prostate cancer
(case reports)
Troglitazone Reduced prostate-speciﬁc antigen [92]
Phase II study on patients with
metastatic colon cancer
Troglitazone No signiﬁcant eﬀect [93]
Phase II study on patients with
liposarcoma
Rosiglitazone Lengthened mean time of progression [94]
Phase II study on patients with
refractory breast cancer
Troglitazone No signiﬁcant eﬀect [95]
Phase II study on patients with
thyroglobulin-positive and
radioiodine-negative
diﬀerentiated thyroid cancer
Rosiglitazone Induced radioiodine uptake [96]
Phase I study on patients with
solid tumors
LY293111 The recommended oral dose (600mg/day) for phase II trial [97]
higher doses and longer duration of rosiglitazone therapy
may be useful to better deﬁne the role of rosiglitazone as a
rediﬀerentiationagentindiﬀerentiatedthyroidcancer.There
is a phase I clinical study of a PPARγ ligand (LY293111)
that is not thiazolidinedione members [97]. LY293111 is a
novel diaryl ether carboxylic acid derivative and is known as
PPARγ agonistandLTB4antagonist.Thestudysuggestedthe
dose (600mg) of LY293111 in combination with irinotecan
(200mg/m2 IV every 21 days for phase II clinical study
against solid tumors.
6. CONCLUSIONS
PPARs were originally recognized to be genetic regulators
of complex pathways of mammalian metabolism, including
fatty acid oxidation and lipogenesis. However, the receptors
have been shown to be implicated in carcinogenesis and
inﬂammation. PPARs are involved in cell proliferation and
diﬀerentiation of a variety of cancer. Numerous reports
indicate that PPARs ligands could play an important role in
prevention and inhibition of cancer development. Synthetic
PPAR ligands used for drugs or those of naturally occurring
lipids are promising cancer chemopreventive agents with
slight side eﬀects against several types of cancer. We should
characterize expression patterns of diﬀerent isoforms of
PPAR in cancerous and precancerous tissues and determine
their precise roles in the carcinogenic process for develop-
ment of PPARs ligands as a novel class of cancer preven-
tive/theraputic drugs. Based on current data from preclinical
and clinical studies, we believe that thiazolidinediones,
especially PPARγ agonists, have important role in short-
term prophylactic therapy designed to reduce the number of
putative preneoplasia, ACF, in patients who are at high risk
for CRC development.
ABBREVIATIONS
AOM: Azoxymethane
APC: Adenomatous polyposis coli
CLA: Conjugated linoleic acid
COX-2: Cyclooxygenase-2
CRC: Colorectal cancer
DSS: Dextran sodium sulfate
LPL: Lipoprotein lipase
LTB4: Leukotriene B4
PG: Prostaglandin
PPARs: Peroxisome proliferators-activated receptor
PPRE: Peroxisome proliferators response element
PSA: Prostate-speciﬁc antigen
PUFA: Polyunsaturated fatty acid
RXR: Retinoid X receptor
TG: Triglyceride
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